These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32640968)

  • 1. Modeling Parkinson's Disease in Zebrafish.
    Najib NHM; Nies YH; Abd Halim SAS; Yahaya MF; Das S; Lim WL; Teoh SL
    CNS Neurol Disord Drug Targets; 2020; 19(5):386-399. PubMed ID: 32640968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental models of chemically induced Parkinson's disease in zebrafish at the embryonic larval stage: a systematic review.
    Briñez-Gallego P; da Costa Silva DG; Cordeiro MF; Horn AP; Hort MA
    J Toxicol Environ Health B Crit Rev; 2023 May; 26(4):201-237. PubMed ID: 36859813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fishing for Parkinson's Disease: A review of the literature.
    Ünal İ; Emekli-Alturfan E
    J Clin Neurosci; 2019 Apr; 62():1-6. PubMed ID: 30660479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal models of Parkinson's disease: similarities and differences between the disease and models.
    Hattori N; Sato S
    Neuropathology; 2007 Oct; 27(5):479-83. PubMed ID: 18018484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substantia Nigra Volume Dissociates Bradykinesia and Rigidity from Tremor in Parkinson's Disease: A 7 Tesla Imaging Study.
    Poston KL; Ua Cruadhlaoich MAI; Santoso LF; Bernstein JD; Liu T; Wang Y; Rutt B; Kerchner GA; Zeineh MM
    J Parkinsons Dis; 2020; 10(2):591-604. PubMed ID: 32250317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electroacupuncture Promotes Recovery of Motor Function and Reduces Dopaminergic Neuron Degeneration in Rodent Models of Parkinson's Disease.
    Lin JG; Chen CJ; Yang HB; Chen YH; Hung SY
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28837077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathogenesis, experimental models and new therapeutic strategies for Parkinson's disease.
    Yamashita H; Matsumoto M
    Regen Med; 2007 Jul; 2(4):447-55. PubMed ID: 17635051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's disease: Autoimmunity and neuroinflammation.
    De Virgilio A; Greco A; Fabbrini G; Inghilleri M; Rizzo MI; Gallo A; Conte M; Rosato C; Ciniglio Appiani M; de Vincentiis M
    Autoimmun Rev; 2016 Oct; 15(10):1005-11. PubMed ID: 27497913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal hippocampal neurogenesis in Parkinson's disease: relevance to a new therapeutic target for depression with Parkinson's disease.
    Lim J; Bang Y; Choi HJ
    Arch Pharm Res; 2018 Oct; 41(10):943-954. PubMed ID: 30136247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teleost Model as an Alternative in Parkinson's Disease.
    Manasa K; Chitra V; Tamilanban T
    Neurol India; 2020; 68(5):979-984. PubMed ID: 33109837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Back and to the Future: From Neurotoxin-Induced to Human Parkinson's Disease Models.
    Airavaara M; Parkkinen I; Konovalova J; Albert K; Chmielarz P; Domanskyi A
    Curr Protoc Neurosci; 2020 Mar; 91(1):e88. PubMed ID: 32049438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's Disease: A Review from Pathophysiology to Treatment.
    Marino BLB; de Souza LR; Sousa KPA; Ferreira JV; Padilha EC; da Silva CHTP; Taft CA; Hage-Melim LIS
    Mini Rev Med Chem; 2020; 20(9):754-767. PubMed ID: 31686637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral Tests in Neurotoxin-Induced Animal Models of Parkinson's Disease.
    Prasad EM; Hung SY
    Antioxidants (Basel); 2020 Oct; 9(10):. PubMed ID: 33081318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling neurodegenerative diseases in vivo review.
    von Bohlen Und Halbach O
    Neurodegener Dis; 2005; 2(6):313-20. PubMed ID: 16909014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease.
    Theisen F; Leda R; Pozorski V; Oh JM; Adluru N; Wong R; Okonkwo O; Dean DC; Bendlin BB; Johnson SC; Alexander AL; Gallagher CL
    Neuroimage Clin; 2017; 16():557-563. PubMed ID: 28971007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classic and evolving animal models in Parkinson's disease.
    Pingale T; Gupta GL
    Pharmacol Biochem Behav; 2020 Dec; 199():173060. PubMed ID: 33091373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.